Jean Hurteau

4.4k total citations · 1 hit paper
90 papers, 3.2k citations indexed

About

Jean Hurteau is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Jean Hurteau has authored 90 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Reproductive Medicine, 31 papers in Oncology and 21 papers in Surgery. Recurrent topics in Jean Hurteau's work include Ovarian cancer diagnosis and treatment (48 papers), PARP inhibition in cancer therapy (19 papers) and Endometrial and Cervical Cancer Treatments (19 papers). Jean Hurteau is often cited by papers focused on Ovarian cancer diagnosis and treatment (48 papers), PARP inhibition in cancer therapy (19 papers) and Endometrial and Cervical Cancer Treatments (19 papers). Jean Hurteau collaborates with scholars based in United States, Canada and United Kingdom. Jean Hurteau's co-authors include Lawrence M. Roth, Regina S. Whitaker, Robert C. Bast, Gregory P. Sutton, Brian N. Bundy, Howard D. Homesley, Katherine Y. Look, Elise C. Kohn, Robert M. Bigsby and S. Diane Yamada and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Jean Hurteau

81 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

2014 446 citations Joyce F. Liu, William T. Barry et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean Hurteau United States	29	1.3k	1.1k	1.1k	664	657	90	3.2k
Kazunori Ochiai Japan	27	1.6k 1.2×	993 0.9×	937 0.8×	659 1.0×	588 0.9×	105	3.2k
Marcus Q. Bernardini Canada	30	1.3k 1.0×	723 0.6×	834 0.7×	1.2k 1.9×	484 0.7×	134	3.1k
Christine Walsh United States	30	1.0k 0.8×	845 0.8×	874 0.8×	687 1.0×	282 0.4×	93	2.6k
Seiji Isonishi Japan	21	969 0.7×	798 0.7×	799 0.7×	367 0.6×	454 0.7×	80	2.2k
Susana M. Campos United States	28	899 0.7×	859 0.8×	1.6k 1.5×	330 0.5×	319 0.5×	101	3.3k
Felix Hilpert Germany	29	2.5k 1.9×	762 0.7×	1.6k 1.4×	829 1.2×	1.0k 1.5×	172	3.9k
Beihua Kong China	32	1.2k 0.9×	1.2k 1.1×	611 0.5×	796 1.2×	311 0.5×	121	3.1k
Lars Hanker Germany	25	724 0.6×	827 0.7×	1.0k 0.9×	336 0.5×	364 0.6×	100	2.4k
Rouba Ali‐Fehmi United States	39	1.3k 1.0×	1.2k 1.0×	811 0.7×	1.6k 2.4×	576 0.9×	152	4.2k
Gilad Ben‐Baruch Israel	39	1.7k 1.3×	1.4k 1.3×	995 0.9×	1.3k 1.9×	510 0.8×	152	4.7k

Countries citing papers authored by Jean Hurteau

Since Specialization

Citations

This map shows the geographic impact of Jean Hurteau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Hurteau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Hurteau more than expected).

Fields of papers citing papers by Jean Hurteau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Hurteau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Hurteau. The network helps show where Jean Hurteau may publish in the future.

Co-authorship network of co-authors of Jean Hurteau

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Hurteau. A scholar is included among the top collaborators of Jean Hurteau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Hurteau. Jean Hurteau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Duska, Linda, Jonathan Lim, Mark A. Guinter, et al.. (2025). The BEV1L study: Do real‐world outcomes associated with the addition of bevacizumab to first‐line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?. Cancer. 131(10). e35821–e35821.

2.

Lim, Jonathan, et al.. (2025). Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer. Future Oncology. 21(2). 213–219.

3.

Chase, Dana M., Jonathan Lim, Mark A. Guinter, et al.. (2025). Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study. Oncology and Therapy. 13(1). 253–262.

4.

Rimel, B.J., Dana M. Chase, Armen A. Ghazarian, et al.. (2024). Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting. Gynecologic Oncology Reports. 51. 101332–101332. 3 indexed citations

5.

Coleman, Robert L., et al.. (2023). Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States. Journal of health economics and outcomes research. 10(2). 82–90. 3 indexed citations

6.

Coleman, Robert L., et al.. (2023). Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States. Journal of health economics and outcomes research. 82–90. 7 indexed citations

7.

Chase, Dana M., B.J. Rimel, Armen A. Ghazarian, et al.. (2023). Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy (2200). Gynecologic Oncology. 176. S257–S257. 1 indexed citations

8.

Rodriguez, Gustavo C., James Kauderer, J. Hunn, et al.. (2019). Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. Cancer Prevention Research. 12(6). 401–412. 1 indexed citations

9.

Bishop, Erin, James Java, Kathleen N. Moore, et al.. (2017). Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology. 218(1). 109.e1–109.e11. 40 indexed citations

10.

Liu, Joyce F., William T. Barry, Michael J. Birrer, et al.. (2014). Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncology. 15(11). 1207–1214. 446 indexed citations breakdown →

11.

Hurteau, Jean, Mark F. Brady, Kathleen M. Darcy, et al.. (2010). Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecologic Oncology. 119(3). 444–450. 56 indexed citations

12.

Rodriguez, Gustavo C., et al.. (2010). The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. Journal of Surgical Oncology. 101(4). 334–343. 25 indexed citations

13.

Mell, Loren K., Jean Hurteau, Yvonne Collins, et al.. (2005). Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. International Journal of Radiation Oncology*Biology*Physics. 61(4). 1078–1086. 70 indexed citations

14.

Hurd, William W., et al.. (2003). Visualization of the epigastric vessels and bladder before laparoscopic trocar placement. Fertility and Sterility. 80(1). 209–212. 16 indexed citations

15.

Hurteau, Jean. (2003). Gestational Trophoblastic Disease: Management of Hydatidiform Mole. Clinical Obstetrics & Gynecology. 46(3). 557–569. 20 indexed citations

16.

Hurteau, Jean, John A. Blessing, Steven DeCesare, & William T. Creasman. (2001). Evaluation of Recombinant Human Interleukin-12 in Patients with Recurrent or Refractory Ovarian Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology. 82(1). 7–10. 73 indexed citations

17.

Hurd, William W., et al.. (2001). Location of the ureters in relation to the uterine cervix by computed tomography. American Journal of Obstetrics and Gynecology. 184(3). 336–339. 30 indexed citations

18.

Hurteau, Jean, et al.. (2001). Regulation of Invasion of Epithelial Ovarian Cancer by Transforming Growth Factor-β. Gynecologic Oncology. 80(2). 245–253. 91 indexed citations

19.

Smucker, Joseph D., Lawrence M. Roth, Gregory P. Sutton, & Jean Hurteau. (1999). Trisomy 21 Associated with Ovarian Dysgerminoma. Gynecologic Oncology. 74(3). 512–514. 11 indexed citations

20.

Moore, David H., et al.. (1998). Gynecologic cancers metastatic to the breast. Journal of the American College of Surgeons. 187(2). 178–181. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact